DK1146896T3 - Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger - Google Patents

Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Info

Publication number
DK1146896T3
DK1146896T3 DK00904496T DK00904496T DK1146896T3 DK 1146896 T3 DK1146896 T3 DK 1146896T3 DK 00904496 T DK00904496 T DK 00904496T DK 00904496 T DK00904496 T DK 00904496T DK 1146896 T3 DK1146896 T3 DK 1146896T3
Authority
DK
Denmark
Prior art keywords
human insulin
modified
acylated
formulations
formulations containing
Prior art date
Application number
DK00904496T
Other languages
Danish (da)
English (en)
Inventor
Kingman Ng
Shun Li
Eric Alan Watts
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1146896T3 publication Critical patent/DK1146896T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK00904496T 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger DK1146896T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11729199P 1999-01-26 1999-01-26
PCT/US2000/001627 WO2000043034A2 (fr) 1999-01-26 2000-01-26 Formulations d'analogues d'insuline acyles hexameres monodisperses

Publications (1)

Publication Number Publication Date
DK1146896T3 true DK1146896T3 (da) 2002-09-02

Family

ID=22372048

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904496T DK1146896T3 (da) 1999-01-26 2000-01-26 Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger

Country Status (9)

Country Link
EP (1) EP1146896B1 (fr)
JP (1) JP2002535287A (fr)
AT (1) ATE220917T1 (fr)
AU (1) AU2624400A (fr)
DE (1) DE60000288T2 (fr)
DK (1) DK1146896T3 (fr)
ES (1) ES2180511T3 (fr)
PT (1) PT1146896E (fr)
WO (1) WO2000043034A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
EP1506003A1 (fr) * 2002-05-07 2005-02-16 Novo Nordisk A/S Preparations solubles comprenant de l'insuline aspart et de l'insuline detemir
AU2003236201A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
EP2626368B1 (fr) 2004-07-19 2016-12-21 Biocon Limited Conjugués insuline-oligomère, formulations et utilisations de ceux-ci
WO2007074133A2 (fr) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprenant de l'insuline acylée et du zinc, et procédés de préparation de celles-ci
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2404934A1 (fr) 2006-09-22 2012-01-11 Novo Nordisk A/S Analogues d'insuline résistants à la protéase
WO2008132224A2 (fr) 2007-04-30 2008-11-06 Novo Nordisk A/S Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
ES2744384T3 (es) 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
WO2009112583A2 (fr) 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
MX360107B (es) 2012-11-13 2018-10-23 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido.
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
JP6499184B2 (ja) 2013-10-07 2019-04-10 ノヴォ ノルディスク アー／エス インスリン類似体の新規な誘導体
TW201630622A (zh) 2014-12-16 2016-09-01 美國禮來大藥廠 速效胰島素組合物
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
BR112019011761A2 (pt) * 2016-12-16 2019-11-05 Novo Nordisk As composições farmacêuticas contendo insulina
IL270975B2 (en) 2017-06-01 2024-02-01 Lilly Co Eli Fast-acting insulin preparations
WO2019034726A1 (fr) 2017-08-17 2019-02-21 Novo Nordisk A/S Nouveaux analogues d'insuline acylés et leurs utilisations
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220289811A1 (en) * 2019-08-16 2022-09-15 Lamark Biotech Pvt Limited A formulation of insulin based on crystal-seeding in hydrogels and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189964B1 (pl) * 1996-06-20 2005-10-31 Novo Nordisk As Wodny preparat insuliny, środek farmaceutyczny dopodawania pozajelitowego oraz sposób poprawiania chemicznej stabilności preparatów insuliny
ATE294189T1 (de) * 1997-02-07 2005-05-15 Novo Nordisk As Kristallisation von proteinen
ATE290877T1 (de) * 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen

Also Published As

Publication number Publication date
ATE220917T1 (de) 2002-08-15
DE60000288D1 (de) 2002-08-29
EP1146896B1 (fr) 2002-07-24
JP2002535287A (ja) 2002-10-22
ES2180511T3 (es) 2003-02-16
PT1146896E (pt) 2002-10-31
WO2000043034A3 (fr) 2000-12-28
WO2000043034A2 (fr) 2000-07-27
AU2624400A (en) 2000-08-07
EP1146896A2 (fr) 2001-10-24
DE60000288T2 (de) 2003-01-16

Similar Documents

Publication Publication Date Title
DK1146896T3 (da) Formuleringer, som indeholder monodisperse hexamere acylerede insulin-analoger
WO2002043750A3 (fr) Procede de stabilisation de biomolecules dans des formulations liquides
HUP0100243A2 (hu) Inzulint és/vagy inzulin-analógokat és azok származékait tartalmazó oldhatatlan készítmények, eljárás azok előállítására és alkalmazásuk a vércukor szintjének szabályozására
EP1808438A3 (fr) Purification et stabilisation de peptide et protéines dans des agents pharmaceutiques
EP1234586A3 (fr) Agents hépatosélectifs à activité pharmaceutique
WO2007130113A3 (fr) Analogues de l'hormone parathyroidienne et procedes les utilisant
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
MY121291A (en) Fracture healing using pthrp analogs
WO2003053346A3 (fr) Systemes et methodes de traitement de patients ayant des cellules aspirees par liposuccion traitees
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
AU2924084A (en) Oral antidiabetic composition
NO20005625L (no) Anvendelse av toremifen og dens metabolske analoger, og deres farmasoytisk akseptable salter, estere, N-oksider og blanding av disse, i fremstilling av et farmasoytisk preparat for behandling av prostataintraepitelisk neoplasi (PIN)
HK1037142A1 (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
WO1996024370B1 (fr) Solutions pharmaceutiques salines non organiques a administration endonasale d'une calcitonine
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
KR950700326A (ko) 파라토르몬 단편, 이것의 제조방법 및 이것을 함유하는 약제(parathyroid hormone fragments, their preparation and medicaments containing the same)
CA2522146A1 (fr) Captage de macromolecules
AR036591A1 (es) Uso de la hl en hiperestimulacion ovarica controlada
HK1157635A1 (en) Metal-binding compounds and uses thereof
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
PT97878A (pt) Processo para a preparacao de uma composicao farmaceutica para uso oftalmico contendo hexetidina ou seus derivados ou sais
TH12479B (th) สูตรผสมของสารคล้ายอินซูลิน